GSK and Ionis announced positive topline results from two pivotal Phase 3 trials (B‑Well 1 and B‑Well 2) of bepirovirsen, an antisense oligonucleotide designed to drive functional cures in chronic hepatitis B. The studies enrolled more than 1,800 patients across multiple regions and met their primary endpoints, the companies said. GSK and Ionis said they will proceed with global regulatory filings based on the data and are outlining next steps for submission dossiers. The development, if approved, would shift care for chronic HBV from lifelong suppression toward finite antisense‑based regimens. Companies did not disclose full datasets in the announcement; detailed readouts and safety analyses are expected ahead of regulatory submissions.